A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome.

Míreanna comhchosúla

• A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).
  de réir: Ballard, C, et al.
  Foilsithe / Cruthaithe: (2008)
• A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (The DART-AD Trial)
  de réir: Ballard, C, et al.
  Foilsithe / Cruthaithe: (2008)
• A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (The DART-AD Trial)
  de réir: Ballard, C, et al.
  Foilsithe / Cruthaithe: (2008)
• Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.
  de réir: Ballard, C, et al.
  Foilsithe / Cruthaithe: (2005)
• The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.
  de réir: Ballard, C, et al.
  Foilsithe / Cruthaithe: (2009)